SEC Form 4 · accession 0001193125-26-257465
Kalaris Therapeutics, Inc. · KLRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Dybbs
Director
Period of report
Jun 3, 2026
Accepted (ET)
Jun 4, 2026 · 4:23 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001754068
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.72 | Jun 3, 2026 | A | 9,000 | A | — | Jun 2, 2036 | Common Stock | 9,000 | 9,000 | D |
Explanation of responses
- F1The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.